Lawsuits against GLP-1 manufacturers are working through federal court. Thousands of plaintiffs have filed claims. Headlines use words like "stomach paralysis" and "class action." The reality is more specific and less dramatic.
Here is what is actually happening in the litigation, what the claims involve, and what it means for people who take these medications.
Where Things Stand in 2026
As of early 2026, the Ozempic litigation has reached a moderate scale but has not produced any settlements or trial verdicts. Key facts:
- Federal cases are consolidated into a multidistrict litigation (MDL) in the Western District of Louisiana
- Approximately 4,000 federal lawsuits have been filed and consolidated as of early 2026
- Most claims involve gastrointestinal injuries — primarily gastroparesis and bowel obstruction
- Novo Nordisk and Eli Lilly maintain that their medications are safe when used as directed
- No bellwether trials have concluded yet — the first test trials are expected in late 2026 or early 2027
Additional state court cases exist but are harder to track. The federal MDL represents the largest concentration of cases.
What Is an MDL?
Multidistrict litigation (MDL) is a legal procedure that consolidates civil cases involving common factual questions into one federal court for pretrial proceedings. It is not a class action.
In a class action, one or a few plaintiffs represent an entire group. Any settlement or verdict applies to everyone in the class automatically. In an MDL, each plaintiff keeps their own individual case. The cases are combined only for discovery, pretrial motions, and bellwether trials. After the pretrial phase, cases that do not settle are sent back to their original federal districts for individual trials.
MDLs are common in pharmaceutical litigation. Recent drug MDLs include the Roundup litigation (approximately 125,000 cases), the Philips CPAP recall litigation (roughly 700 cases), and the Zantac litigation (over 2,000 cases before its dismissal in 2022).
The Ozempic MDL Specifically
The GLP-1 litigation is formally designated MDL No. 3024, titled In re: Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Products Liability Litigation. It is overseen by Judge Kenneth M. Hoyt in the U.S. District Court for the Western District of Louisiana.
The JPML (Judicial Panel on Multidistrict Litigation) consolidated the cases in February 2024. The consolidation covers lawsuits involving semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) manufactured by Novo Nordisk and Eli Lilly.
Gastroparesis Claims: The Core of the Litigation
Gastroparesis is the most common injury alleged in the Ozempic MDL. Understanding these claims requires separating what the science establishes from what the lawsuits allege.
What Is Gastroparesis?
Gastroparesis is a condition in which the stomach takes an abnormally long time to empty its contents into the small intestine. Symptoms include persistent nausea, vomiting, early fullness, bloating, and abdominal pain. In severe cases, patients may require feeding tubes or hospitalization.
Gastroparesis can be caused by diabetes (the most common cause), surgical nerve damage, certain medications, and autoimmune conditions. In many cases, no clear cause is identified.
What the Science Says About GLP-1s and Gastric Emptying
This is where the science and the litigation intersect. Delayed gastric emptying is a known, intended pharmacological effect of GLP-1 receptor agonists. It is how these medications help control blood sugar and reduce appetite. The prescribing information for Ozempic explicitly states that semaglutide delays gastric emptying.
The key question in the litigation is whether this known pharmacological effect crosses into pathology — that is, whether the delay becomes severe enough or persistent enough to constitute gastroparesis as a clinical diagnosis rather than a tolerable side effect.
A 2022 study in Diabetes Care found that semaglutide delayed gastric emptying by approximately 40% compared to placebo at the 14-week mark in patients with type 2 diabetes. This delay was measurable but not necessarily pathologic. Most clinical trial participants did not develop gastroparesis.
However, the FDA Adverse Event Reporting System (FAERS) database has received reports of gastroparesis in patients taking GLP-1 medications. The American Gastroenterological Association published a 2024 clinical practice update noting that GLP-1-associated gastroparesis appears to be uncommon but real, and that most cases improve after discontinuation of the medication.
The lawsuits allege that Novo Nordisk and Eli Lilly knew or should have known that the delayed gastric emptying effect could become pathologic in some patients, and that the warning labels did not adequately communicate this risk.
How Many Plaintiffs Allege Gastroparesis?
The exact breakdown of injury types in the MDL has not been publicly detailed in a single filing. However, legal analysts and court filings indicate that gastroparesis and related delayed gastric emptying injuries account for the majority of claims — likely 70% or more of the consolidated cases.
Bowel Obstruction and Ileus Claims
The second major category of claims involves bowel obstruction and paralytic ileus.
Bowel obstruction means a blockage that prevents food or liquid from passing through the intestines. Ileus refers to a temporary cessation of intestinal peristalsis — the wave-like muscle contractions that move contents through the digestive tract — without a physical blockage.
The FDA added a precaution about ileus to the Ozempic label in September 2023 after receiving adverse event reports. The prescribing information now includes a warning that GLP-1 receptor agonists have been associated with reports of ileus. Novo Nordisk updated Wegovy and Ozempic labeling accordingly.
Plaintiffs allege that the warning came too late — that the companies should have included this risk in the original labeling and that earlier warnings might have prevented their injuries.
Some cases in the MDL involve patients who required surgery to relieve bowel obstructions. Others involve hospitalization for ileus that resolved with supportive care.
Thyroid Cancer Claims
All GLP-1 receptor agonists carry an FDA-mandated boxed warning about the risk of thyroid C-cell tumors. The warning is based on rodent studies in which GLP-1 receptor agonists caused medullary thyroid carcinoma in rats and mice.
The rodent data is clear. The human data is not. Multiple large epidemiological studies have found no increased risk of thyroid cancer in humans taking GLP-1 medications. A 2024 retrospective cohort study published in JAMA Otolaryngology–Head & Neck Surgery analyzing data from over 2 million patients found no statistically significant association between GLP-1 use and thyroid cancer after adjusting for confounders.
The disconnect exists because rodent thyroid C-cells have GLP-1 receptors that behave differently than human C-cells. Whether the rodent findings translate to humans remains an open scientific question, but the current evidence does not support a strong link.
Thyroid cancer claims represent a smaller portion of the MDL compared to gastrointestinal claims. They are included because the boxed warning exists and plaintiffs argue the warning should have been stronger or that the drugs should not have been approved given the rodent data.
Timeline of Key Events
- 2017: Ozempic (semaglutide) receives FDA approval for type 2 diabetes
- 2021: Wegovy (semaglutide 2.4 mg) receives FDA approval for weight management
- 2022: Mounjaro (tirzepatide) receives FDA approval for type 2 diabetes
- 2023: First individual lawsuits filed in federal courts alleging gastroparesis and bowel obstruction from GLP-1 medications
- September 2023: FDA adds ileus warning to Ozempic and Wegovy prescribing information
- February 2024: The JPML consolidates federal GLP-1 lawsuits into MDL 3024 in the Western District of Louisiana, assigning the case to Judge Kenneth Hoyt
- 2024: Case filings accelerate. Plaintiffs' leadership committees are appointed. Discovery begins
- 2025: General discovery and expert depositions continue. Novo Nordisk and Eli Lilly file motions challenging the scientific basis of some claims
- Early 2026: Approximately 4,000 cases consolidated in the MDL. Bellwether trial selection underway
- Late 2026 (expected): First bellwether trials may begin, depending on pretrial rulings
What the Manufacturers Say
Novo Nordisk has stated that gastrointestinal side effects of Ozempic and Wegovy are described in the prescribing information and that the company stands behind the safety profile of its medications when used as directed. In court filings, the company has argued that the label adequately warns about delayed gastric emptying and that gastroparesis is a known complication of diabetes itself — making it difficult to attribute causation to the medication rather than the underlying disease.
Eli Lilly has made similar statements regarding Mounjaro and Zepbound. The company has noted that the prescribing information for tirzepatide includes warnings about gastrointestinal effects and that adverse event reporting does not establish causation.
Both companies have also emphasized that GLP-1 medications have undergone extensive clinical testing and that the benefit-risk profile remains favorable for approved indications.
How This Compares to Other Drug MDLs
Drug MDLs vary widely in size, duration, and outcome. Some context:
- Vioxx (meridia/rofecoxib): Merck faced approximately 27,000 lawsuits before settling for $4.85 billion in 2007, three years after the drug was withdrawn from the market.
- Roundup (glyphosate): Over 125,000 cases. Bayer has paid more than $10 billion in settlements since 2020.
- Zantac (ranitidine): Approximately 2,000 cases were consolidated before the MDL was dismissed in 2022 after the court found insufficient scientific evidence that ranitidine causes cancer.
- Philips CPAP recall: Roughly 700 cases consolidated. Settlements began in 2023.
The GLP-1 MDL is moderate in size at roughly 4,000 cases. It is unusual in that the medications at issue remain on the market, remain FDA-approved, and continue to be widely prescribed. Most large drug MDLs involve products that have been withdrawn or restricted.
Timeline expectations: Drug MDLs typically take 3 to 7 years from consolidation to resolution through settlement or trial. The GLP-1 MDL was consolidated in February 2024, so resolution before 2027 is unlikely. If bellwether trials produce plaintiff verdicts, settlement pressure increases. If defense verdicts dominate, cases may decline.
Should You Join a Lawsuit?
Most people who take GLP-1 medications and experience side effects do not have a viable legal claim. Here is why:
- The MDL is not a class action. You cannot simply "sign up." Each case requires individual filing, individual medical records, and individual proof that the medication caused a specific injury.
- Most online ads are lead generation. Law firms advertising "Ozempic lawsuit" on social media are typically collecting client leads, not announcing existing class actions you can join. These firms may or may not take your case after screening.
- Causation is difficult to prove. If you have diabetes, gastroparesis may be a complication of your underlying condition rather than the medication. Defense attorneys will argue this.
- The process takes years. Even if you have a strong case, resolution through settlement or trial is likely years away.
- You need documented injury. Having nausea or vomiting that resolved does not typically support a lawsuit. Plaintiffs in the MDL generally have documented diagnoses of gastroparesis, bowel obstruction requiring surgery, or other serious injuries with medical records.
If you believe you have a genuine claim, contact a lawyer directly. Do not rely on social media ads or marketing calls. Look for attorneys with experience in pharmaceutical litigation and check their bar standing.
What This Means If You Take GLP-1 Medications
The existence of lawsuits does not mean the medication is unsafe. Lawsuits are allegations, not findings of fact. Key points:
- Do not stop your medication because of litigation. Talk to your prescribing doctor first.
- Report unusual symptoms. Persistent vomiting, severe abdominal pain, or inability to keep food down should prompt a medical visit. These could indicate gastroparesis or obstruction.
- Stay informed through reliable sources. Court filings, FDA updates, and peer-reviewed research are more reliable than social media posts or law firm advertisements.
- File adverse event reports if appropriate. The FDA MedWatch system collects reports that help regulators monitor drug safety. You can file a report at fda.gov/safety/medwatch.
Helpful Products for GLP-1 Treatment
If you are managing side effects from your GLP-1 medication, these products may help:
- Sharps container — Required for safe needle disposal at home. A sharps container prevents accidental needle sticks.
- Ginger products — May help manage nausea. Ginger chews or ginger tea are common options.
- Water bottle — Staying hydrated reduces constipation risk and supports overall GI function. A large water bottle helps you track intake.
- Electrolyte packets — Help prevent dehydration from nausea or vomiting. Electrolyte packets dissolve easily in water.
GLPSpot may earn from qualifying purchases.
How to Report Side Effects
- FDA MedWatch: The FDA's adverse event reporting program at fda.gov/safety/medwatch
- Your doctor: They can help determine if symptoms are medication-related and report on your behalf
- The manufacturer: Novo Nordisk and Eli Lilly both maintain adverse event reporting lines
The Bottom Line
Lawsuits against GLP-1 manufacturers are ongoing and will likely continue for several more years. The core claims involve gastroparesis and bowel obstruction, with a smaller number of thyroid cancer cases. No court has found that GLP-1 medications cause these injuries. The MDL process is still in pretrial stages. Most online lawsuit advertisements are marketing by law firms, not invitations to join an existing class action. If you take a GLP-1 medication, the litigation does not change your treatment plan. Talk to your doctor about any concerns.
This article is for information only and is not legal or medical advice. To report adverse events to the FDA, visit fda.gov/safety/medwatch.
